Halozyme Therapeutics Stock Forecast - Naive Prediction
| HALO Stock | USD 70.22 0.35 0.50% |
Halozyme Stock outlook is based on your current time horizon. Although Halozyme Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Halozyme Therapeutics' systematic risk associated with finding meaningful patterns of Halozyme Therapeutics fundamentals over time.
As of today, The RSI of Halozyme Therapeutics' share price is at 53. This usually indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Halozyme Therapeutics, making its price go up or down. Momentum 53
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 0.362 | EPS Estimate Next Quarter 0.9562 | EPS Estimate Current Year 6.254 | EPS Estimate Next Year 8.21 | Wall Street Target Price 77.125 |
Using Halozyme Therapeutics hype-based prediction, you can estimate the value of Halozyme Therapeutics from the perspective of Halozyme Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Halozyme Therapeutics using Halozyme Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Halozyme using crowd psychology based on the activity and movement of Halozyme Therapeutics' stock price.
Halozyme Therapeutics Short Interest
An investor who is long Halozyme Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Halozyme Therapeutics and may potentially protect profits, hedge Halozyme Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 64.3385 | Short Percent 0.1635 | Short Ratio 6.47 | Shares Short Prior Month 12.5 M | 50 Day MA 68.8178 |
Halozyme Relative Strength Index
The Naive Prediction forecasted value of Halozyme Therapeutics on the next trading day is expected to be 65.62 with a mean absolute deviation of 1.53 and the sum of the absolute errors of 94.88.Halozyme Therapeutics Hype to Price Pattern
Investor biases related to Halozyme Therapeutics' public news can be used to forecast risks associated with an investment in Halozyme. The trend in average sentiment can be used to explain how an investor holding Halozyme can time the market purely based on public headlines and social activities around Halozyme Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Halozyme Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Halozyme Therapeutics.
Halozyme Therapeutics Implied Volatility | 0.51 |
Halozyme Therapeutics' implied volatility exposes the market's sentiment of Halozyme Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Halozyme Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Halozyme Therapeutics stock will not fluctuate a lot when Halozyme Therapeutics' options are near their expiration.
The Naive Prediction forecasted value of Halozyme Therapeutics on the next trading day is expected to be 65.62 with a mean absolute deviation of 1.53 and the sum of the absolute errors of 94.88. Halozyme Therapeutics after-hype prediction price | USD 70.22 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Halozyme Therapeutics to cross-verify your projections. Prediction based on Rule 16 of the current Halozyme contract
Based on the Rule 16, the options market is currently suggesting that Halozyme Therapeutics will have an average daily up or down price movement of about 0.0319% per day over the life of the 2026-03-20 option contract. With Halozyme Therapeutics trading at USD 70.22, that is roughly USD 0.0224 . If you think that the market is fully incorporating Halozyme Therapeutics' daily price movement you should consider acquiring Halozyme Therapeutics options at the current volatility level of 0.51%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 Halozyme Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Halozyme Therapeutics' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Halozyme Therapeutics' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Halozyme Therapeutics stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Halozyme Therapeutics' open interest, investors have to compare it to Halozyme Therapeutics' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Halozyme Therapeutics is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Halozyme. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Halozyme Therapeutics Additional Predictive Modules
Most predictive techniques to examine Halozyme price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Halozyme using various technical indicators. When you analyze Halozyme charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Halozyme Therapeutics Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Halozyme Therapeutics' financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2002-03-31 | Previous Quarter 61.9 M | Current Value 419.7 M | Quarterly Volatility 96.2 M |
Halozyme Therapeutics Naive Prediction Price Forecast For the 29th of January
Given 90 days horizon, the Naive Prediction forecasted value of Halozyme Therapeutics on the next trading day is expected to be 65.62 with a mean absolute deviation of 1.53, mean absolute percentage error of 3.93, and the sum of the absolute errors of 94.88.Please note that although there have been many attempts to predict Halozyme Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Halozyme Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Halozyme Therapeutics Stock Forecast Pattern
| Backtest Halozyme Therapeutics | Halozyme Therapeutics Price Prediction | Buy or Sell Advice |
Halozyme Therapeutics Forecasted Value
In the context of forecasting Halozyme Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Halozyme Therapeutics' downside and upside margins for the forecasting period are 63.71 and 67.53, respectively. We have considered Halozyme Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Halozyme Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Halozyme Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 121.3178 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.5303 |
| MAPE | Mean absolute percentage error | 0.0224 |
| SAE | Sum of the absolute errors | 94.8758 |
Predictive Modules for Halozyme Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Halozyme Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Halozyme Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Halozyme Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Halozyme Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Halozyme Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Halozyme Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Halozyme Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Halozyme Therapeutics' historical news coverage. Halozyme Therapeutics' after-hype downside and upside margins for the prediction period are 68.31 and 72.13, respectively. We have considered Halozyme Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Halozyme Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Halozyme Therapeutics is based on 3 months time horizon.
Halozyme Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Halozyme Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.16 | 1.91 | 0.35 | 0.08 | 12 Events / Month | 7 Events / Month | In about 12 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
70.22 | 70.22 | 0.00 |
|
Halozyme Therapeutics Hype Timeline
Halozyme Therapeutics is currently traded for 70.22. The entity has historical hype elasticity of 0.35, and average elasticity to hype of competition of -0.08. Halozyme is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is about 88.02%. The immediate return on the next news is expected to be very small, whereas the daily expected return is currently at 0.16%. %. The volatility of related hype on Halozyme Therapeutics is about 403.81%, with the expected price after the next announcement by competition of 70.14. About 99.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Halozyme Therapeutics had 171:40 split on the 10th of December 2003. Given the investment horizon of 90 days the next expected press release will be in about 12 days. Check out Historical Fundamental Analysis of Halozyme Therapeutics to cross-verify your projections.Halozyme Therapeutics Related Hype Analysis
Having access to credible news sources related to Halozyme Therapeutics' direct competition is more important than ever and may enhance your ability to predict Halozyme Therapeutics' future price movements. Getting to know how Halozyme Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Halozyme Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CORT | Corcept Therapeutics Incorporated | (1.61) | 9 per month | 0.00 | (0.06) | 6.49 | (7.08) | 58.23 | |
| ABVX | Abivax SA American | (5.17) | 24 per month | 3.31 | 0.09 | 6.94 | (6.09) | 29.38 | |
| RYTM | Rhythm Pharmaceuticals | 0.49 | 7 per month | 0.00 | (0.03) | 4.03 | (5.14) | 18.69 | |
| CYTK | Cytokinetics | (1.64) | 10 per month | 2.16 | 0.07 | 4.59 | (3.55) | 10.86 | |
| MRUS | Merus BV | 0.02 | 4 per month | 0.60 | 0.09 | 0.51 | (0.23) | 36.44 | |
| JAZZ | Jazz Pharmaceuticals PLC | 0.02 | 18 per month | 1.68 | 0.08 | 3.66 | (3.14) | 25.96 | |
| CAI | Caris Life Sciences | 0.02 | 14 per month | 0.00 | (0.07) | 4.40 | (4.27) | 21.66 | |
| GRFS | Grifols SA ADR | (2.48) | 18 per month | 0.00 | (0.05) | 3.17 | (3.19) | 8.69 | |
| HSIC | Henry Schein | 0.18 | 10 per month | 1.10 | 0.12 | 2.43 | (1.97) | 13.60 | |
| ATR | AptarGroup | 5.44 | 11 per month | 0.00 | (0.08) | 1.73 | (2.49) | 7.63 |
Other Forecasting Options for Halozyme Therapeutics
For every potential investor in Halozyme, whether a beginner or expert, Halozyme Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Halozyme Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Halozyme. Basic forecasting techniques help filter out the noise by identifying Halozyme Therapeutics' price trends.Halozyme Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Halozyme Therapeutics stock to make a market-neutral strategy. Peer analysis of Halozyme Therapeutics could also be used in its relative valuation, which is a method of valuing Halozyme Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Halozyme Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Halozyme Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Halozyme Therapeutics shares will generate the highest return on investment. By undertsting and applying Halozyme Therapeutics stock market strength indicators, traders can identify Halozyme Therapeutics entry and exit signals to maximize returns.
Halozyme Therapeutics Risk Indicators
The analysis of Halozyme Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Halozyme Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting halozyme stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 1.42 | |||
| Semi Deviation | 1.69 | |||
| Standard Deviation | 1.85 | |||
| Variance | 3.42 | |||
| Downside Variance | 3.19 | |||
| Semi Variance | 2.87 | |||
| Expected Short fall | (1.49) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Halozyme Therapeutics
The number of cover stories for Halozyme Therapeutics depends on current market conditions and Halozyme Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Halozyme Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Halozyme Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Halozyme Therapeutics Short Properties
Halozyme Therapeutics' future price predictability will typically decrease when Halozyme Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Halozyme Therapeutics often depends not only on the future outlook of the potential Halozyme Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Halozyme Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 129.4 M | |
| Cash And Short Term Investments | 596.1 M |
Check out Historical Fundamental Analysis of Halozyme Therapeutics to cross-verify your projections. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.362 | Earnings Share 4.74 | Revenue Per Share | Quarterly Revenue Growth 0.221 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.